MINPP1 (multiple inositol-polyphosphate phosphatase 1) is a histidine phosphatase that hydrolyzes highly phosphorylated inositol polyphosphates, particularly inositol hexakisphosphate (IP6) and inositol pentakisphosphate, into less phosphorylated derivatives 1. By regulating inositol polyphosphate pools, MINPP1 controls the availability of intracellular calcium and iron, which are critical for neuronal development and homeostasis 2. Additionally, MINPP1 exhibits dual substrate specificity, functioning as a 2,3-bisphosphoglycerate 3-phosphatase in glycolytic regulation 3. Loss-of-function MINPP1 mutations cause pontocerebellar hypoplasia type 16 (PCH16), characterized by accumulation of IP6 and subsequent pathological metal chelation that impairs neuronal differentiation and causes brain atrophy 2, 4. MINPP1 variants are also associated with follicular thyroid carcinoma, where LOH at the MINPP1 locus occurs in approximately 25% of tumors, potentially acting as a low-penetrance predisposition allele 5. Recent evidence demonstrates MINPP1 promotes ferroptosis in hepatitis B virus-associated hepatocellular carcinoma via the MINPP1-ZRANB1-CTSB axis 3. MINPP1 expression increases under cellular stress conditions and influences apoptotic responses 6. Higher MINPP1 plasma levels correlate with improved CD4+ T-cell recovery in HIV-positive patients receiving antiretroviral therapy 7.